Remarkably, immune–gene expression signatures reflecting an increased recruitment of activated NK and T cells in breast tumors (i.e., CD8A, CD247, CD3D, GZMA) have been shown to be predictive of clinical benefit from preoperative and adjuvant trastuzumab-based treatment (52, 63, 64). The gene discussed is CD8A; the disease is breast neoplasm.